ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 145 filers reported holding ACLARIS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.60 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,618,965 | -33.9% | 1,258,243 | 0.0% | 13.75% | +44.3% |
| Q2 2023 | $13,047,980 | +28.2% | 1,258,243 | 0.0% | 9.53% | +26.7% |
| Q1 2023 | $10,179,186 | -48.6% | 1,258,243 | 0.0% | 7.52% | -51.1% |
| Q4 2022 | $19,817,327 | +0.1% | 1,258,243 | 0.0% | 15.39% | +1.1% |
| Q3 2022 | $19,805,000 | +12.8% | 1,258,243 | 0.0% | 15.23% | +24.1% |
| Q2 2022 | $17,565,000 | -19.0% | 1,258,243 | 0.0% | 12.27% | +38.5% |
| Q1 2022 | $21,692,000 | +18.6% | 1,258,243 | 0.0% | 8.86% | +97.1% |
| Q4 2021 | $18,295,000 | -19.2% | 1,258,243 | 0.0% | 4.50% | -36.1% |
| Q3 2021 | $22,648,000 | +2.5% | 1,258,243 | 0.0% | 7.04% | -19.0% |
| Q2 2021 | $22,095,000 | -30.3% | 1,258,243 | 0.0% | 8.69% | -6.7% |
| Q1 2021 | $31,708,000 | – | 1,258,243 | – | 9.32% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |